Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:32 PM
Ignite Modification Date:
2025-12-24 @ 10:32 PM
NCT ID:
NCT06523335
Eligibility Criteria:
Inclusion criteria for aged matched healthy group
* Male or female whose age range between 40 and 75
* no known neurological injuries
Exclusion criteria for aged matched healthy group
* have an orthopedic disorder involving upper limbs;
* have a history of any neurologic disease;
* have any history of epilepsy of the potential participants and/or their family members;
* are unable to consent;
* are pregnant.
Inclusion criteria for stroke group
* male or female hemiparetic chronic stroke survivors;
* age ranging between 40-75 year;
* with single unilateral ischemic or hemorrhagic middle cerebral artery stroke;
* neurologically stable for \>6 months;
* have an expectation that current medication will be maintained without changes for at least 3 months. Stable use of anti-spasticity medication (e.g., baclofen, diazepam, tizanidine) is accepted;
* without severe spasticity (Modified Ashworth (MA) \<4);
* have not received botulinum toxin on the impaired arm within 3 months.
Exclusion criteria for stroke group
* have an orthopedic disorder involving upper limbs;
* cognitive impairment sufficient to interfere with informed consent or successful completion of the protocol (Montreal Cognitive Assessment (MoCA) score \< 26);
* a history of another neurologic disease;
* anesthesia of joint position sense in upper limbs;
* are pregnant or have a chance that they might be (self-reported);
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
40 Years
Maximum Age:
75 Years
Study:
NCT06523335
Study Brief:
Protocol Section:
NCT06523335